Orphazyme A/S (ORPHY)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 35.31M |
| EPS (ttm) | -3.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | 1.07 |
| Analysts | Sell |
| Price Target | 14.24 |
| Earnings Date | n/a |
About ORPHY
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, In...
Analyst Forecast
According to 9 analysts, the average rating for ORPHY stock is "Sell." The 12-month stock price forecast is 14.24, which is a change of from the latest price.
News
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPhar...
Orphazyme A/S in restructuring Company announcement No. 24/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme announces update on in-court restructuring proceedings
Orphazyme A/S in restructuring Company announcement No. 23/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs
Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for ...
Dear ORPH Stock Fans, Mark Your Calendars for March 31
After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling. The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appe...
Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of N...
Orphazyme A/S Company announcement No. 13/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme A/S has filed for voluntary delisting of ADSs
Orphazyme A/S Company announcement No. 12/2022 www.orphazyme.com Company Registration No. 32266355
Notice of in-court restructuring proceedings of Orphazyme A/S
Orphazyme A/S Company announcement No. 11/2022 www.orphazyme.com Company Registration No. 32266355
Why Is Orphazyme (ORPH) Stock Up Today?
The troubled biotech company's share price is up 40% despite plans to delist from the Nasdaq exchange and lay off 50% of its workers. The post Why Is Orphazyme (ORPH) Stock Up Today?
Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce
Orphazyme A/S's (NASDAQ: ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine whet...
Commencement of in-court restructuring of Orphazyme A/S
Orphazyme A/S Company announcement No. 10/2022Inside information www.orphazyme.com Company Registration No. 32266355
Anders Vadsholt takes over as CEO of Orphazyme
Company announcement No. 08/2022 www.orphazyme.com Company Registration No. 32266355
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease c...
EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application
Orphazyme A/S (NASDAQ: ORPH) has been notified by the Committee for Medicinal Products for Human Use (CHMP) of a negative trend vote on arimoclomol application following an Oral Explanation. The applica...
Orphazyme announces update on regulatory review of arimoclomol in the European Union
Orphazyme A/S Company ann ouncement No. 07/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease c...
Trading Penny Stocks? Top Stock Market News for February 11th, 2022
What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 11th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | P...
Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type...
Orphazyme A/S Investor n ews No. 02/2022 www.orphazyme.com Company Registration No. 32266355
Orphazyme to present additional data on arimoclomol's mechanism of action during 2022 Annual WORLDSymposium™
Orphazyme A/S Investor News No. 01/2022 www.orphazyme.com Company Registration No. 32266355
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
Orphazyme A/S Company announcement No. 03/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme Tightens FY21 Revenue Outlook
Orphazyme A/S (NASDAQ: ORPH) expects FY21 sales of DKK 35 million – DKK 37 million, compared to the previous guidance of DKK 30 million – DKK 40 million. It anticipates operating expenses of DKK 665 mil...
Orphazyme updates 2021 financial outlook
Orphazyme A/SCompany announcement No. 01/2022Inside information Company Registration No. 32266355
Orphazyme announces changes to the Board of Directors
Orphazyme A/SCompany announcement No. 27/2021Company Registration No. 32266355
All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hot Penny Stocks to Buy Right Now? 3 to Watch Next Week
Which penny stocks are on your November watchlist? The post Hot Penny Stocks to Buy Right Now?